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ABSTRACT
Objective To determine the effect of prescription opioid
use in the year before surgery on opioid consumption
after surgery.
Background Recently developed postoperative opioid
prescribing guidelines rely on data from opioid-naïve
patients. However, opioid use in the USA is common, and
the impact of prior opioid exposure on the consumption
of opioids after surgery is unclear.
Methods Population-based cohort study of 26,001
adults 18 years of age and older who underwent one of
nine elective general or gynecologic surgical procedures
between January 1, 2017 and October 31, 2019, with
prospectively collected patient-reported data from the
Michigan Surgical Quality Collaborative (MSQC) linked
to state prescription drug monitoring program at 70
MSQC-participating hospitals on 30-day patient-reported
opioid consumption in oral morphine equivalents (OME)
(primary outcome).
Results Compared with opioid-naïve participants,
opioid-exposed participants (26% of sample) consumed
more prescription opioids after surgery (adjusted OME
difference 12, 95% CI 10 to 14). Greater opioid exposure
was associated with higher postoperative consumption in
a dose-dependent manner, with chronic users reporting
the greatest consumption (additional OMEs 32, 95% CI
21 to 42). However, for eight of nine procedures, 90%
of opioid-exposed participants consumed ≤150 OMEs.
Among those receiving perioperative prescriptions,
opioid-exposed participants had higher likelihood of refill
(adjusted OR 4.7, 95% CI 4.4 to 5.1), number of refills
(adjusted incidence rate ratio 4.0, 95% CI 3.7 to 4.3),
and average refill amount (adjusted OME difference 333,
95% CI 292 to 374)).
Conclusions Preoperative opioid use is associated with
small increases in patient-reported opioid consumption
after surgery for most patients, though greater
differences exist for patients with chronic use. For most
patients with preoperative opioid exposure, existing
guidelines may meet their postoperative needs. However,
guidelines may need tailoring for patients with chronic
use, and providers should anticipate a higher likelihood
of postoperative refills for all opioid-exposed patients.

INTRODUCTION

Excess opioid prescribing continues to play a
role in the opioid crisis in the USA. As overdose
deaths reach new peaks, more than one in three
opioid overdose deaths have been found to involve
prescription opioids.1 Surgical prescribing has been

increasingly implicated as a key contributor to this
problem.2 Opioid prescribing in the perioperative
setting results in leftover tablets, new persistent use
of opioids, and escalation in doses after surgery for
patients on chronic opioid therapy, all of which
related harms to patients, their
increase opioid-
families, and communities.3 4
To optimize prescribing of opioids after
surgery, best practices and recommendations from
prescribing guidelines aim to balance adequate
pain control while minimizing the risks of overdriven guidelines for surgical
prescribing.5 Data-
prescribing have advanced this effort by relying on
patients to report their actual opioid consumption
after surgery alongside measures of pain and satisfaction. For example, the use of procedure-specific
prescribing guidelines based on patient-
reported
opioid consumption has been shown to markedly
reduce postoperative opioid prescribing while
providing satisfactory pain care.6 7 Nonetheless,
these studies either focus solely on opioid-
naïve
patients or do not distinguish between opioid-
naïve and opioid-exposed patients. As such, current
prescribing recommendations are not tailored to
preoperative opioid exposure.8 Despite this, opioid
exposure before surgery has been shown to result in
worse outcomes for patients, including higher costs,
longer length of stay, and greater risk for postoperative complications.9 10
Opioid use before surgery is common, with estimates suggesting that up to 1 in three adults report
the use of opioid medications in the past year before
surgery.3 9 Therefore, understanding the impact of
opioid exposure before surgery on postoperative
opioid use is critical to calibrate prescribing to
meet patients’ needs, eliminate excess prescribing,
and ensure a safe and comfortable postoperative
recovery. In this context, we sought to determine
how opioid use in the year prior to surgery influences opioid consumption in the month following
common surgical procedures. We hypothesized
that preoperative opioid exposure will be associated with greater opioid consumption after surgery
when compared with opioid-
naïve patients. In
addition, we hypothesized that patients with
opioid exposure before surgery will have higher
rates of consuming any opioids after surgery and
greater postoperative prescribing as evidenced by
larger prescription sizes and higher rates of opioid
prescription refills.
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We retrospectively analyzed prospectively collected data from 70
hospitals participating in the Michigan Surgical Quality Collaborative (MSQC), a patient safety organization that captures data
on participants undergoing general and gynecologic surgical
procedures. As previously described, the MSQC database
includes demographic, perioperative, clinical, and mortality
characteristics collected via postoperative surveys.11 Patient-
reported outcomes including patient-reported opioid consumption are collected using surveys administered between days 30
and 90 following discharge. A sampling algorithm facilitates case
review while minimizing selection bias and ensuring a representative sample.12 Data integrity was enhanced via collection
and audit by MSQC-trained nurse reviewers using standardized
data definitions, with data checks and assessments for accuracy
by a centralized coordinated center.11 Data from MSQC was
then linked to data from the Michigan Automated Prescription
System, which serves as the state’s prescription drug monitoring
program (PDMP) and aggregates data on all controlled substance
fills in the state of Michigan. To safeguard participant privacy,
linkage followed a state-approved process and was accomplished
by a third party that removed all protected health information
from the final dataset.

categories based on quantity and duration: (1) naïve, no opioid
prescription fills; (2) minimal,≤1 month fill with <675 OMEs
(ie, 90 pills of oxycodone 5 mg); (3) intermittent, between
1 month with ≥675 OMEs and 8 months filled; and (4) chronic
≥9 months filled.9
Demographic data included age, sex, race/ethnicity, and insurance type. Patient characteristics included American Society of
Anesthesiologists (ASA) physical status classification, alcohol
use, body mass index (BMI) (<25, 25 to <30, 30 to <35, ≥35),
tobacco use over past year, and relevant patient comorbidities.
Procedure and clinical characteristics included type of surgery,
admission status (inpatient vs outpatient), surgical priority (elective vs urgent/emergent), and length of stay (days).

Outcomes

The primary outcome was patient-
reported opioid consumption after discharge from surgery, defined as the amount of
prescription opioids reported as consumed by patients in the
30-day postoperative period from MSQC. Secondary outcomes
included likelihood of patient-
reported opioid consumption
after surgery, number and likelihood of opioid refills, and the
average amount of opioid refill, defined as the quantity in OMEs
for any fills after the initial perioperative prescription and within
30 days of discharge.

Study cohort and period

We included participants undergoing surgery from January 1,
2017 to October 31, 2019. The study cohort consisted of adult
patients ≥18 years who underwent elective, emergent or urgent
surgery in outpatient and inpatient settings. Surgical procedures
included laparoscopic appendectomy, laparoscopic cholecystectomy, colectomy (laparoscopic or open), hernia (abdominal
or minor), and hysterectomy (laparoscopic, vaginal, or total
abdominal). We excluded patients who lacked self-reported data
on consumption, who had discrepant discharge opioid prescription data between PDMP and MSQC, who had multiple PDMP
matches, who underwent additional surgeries within 90 days
following the index operation, who were not discharged home,
who had a length of stay >30 days, and who had 30-day readmissions, reoperations, or complications. Patients without valid
opioid prescription data, surgeon data, or who resided outside
the state of Michigan were also excluded. We defined the study
period for the year before surgery as spanning 365 days before
to 31 days before surgery. The perioperative period for the first
opioid prescription fill spanned 30 days before to 3 days after
surgery. Refills were identified as additional fills after the initial
prescription within 30 days of discharge after surgery.

Opioid exposures and covariates

The key explanatory variable was preoperative opioid exposure
(yes/no), defined as any opioid fill in the year before surgery
from the PDMP. Opioid prescriptions in MSQC were defined
using names from the Centers for Disease Control and Prevention, which included tramadol but not methadone or buprenorphine.13 The amount of consumed opioids as reported by
patients after surgery came from MSQC. Opioid pharmacy fills
(type, dose, quantity) during the study period came from the
PDMP, which included buprenorphine. These were standardized
to oral morphine equivalents (OME).13 Report of opioid fill in
the perioperative period by either PDMP or MSQC was used to
indicate an opioid fill.
Opioid exposure in the year before surgery from PDMP data
was classified into four groups adapted from a machine learning
cluster analysis technique, with the following mutually exclusive

Statistical analysis

Baseline clinical and prescribing patterns for subgroups of
participants were characterized using descriptive statistics.
Opioid amounts were reported in median OMEs, IQR, and
ranges. Initial comparisons of outcomes for opioid-naïve and
opioid-exposed participants were performed using χ2 or t-tests.
Generalized linear mixed models were used to examine association of preoperative opioid exposure with each outcome. To
account for clustering within surgeons, surgeon was included as
a random effect. Robust standard errors were used for models
with the primary outcome of opioid consumption and opioid
amount in refills. A Gaussian distribution/identity link function
was used to determine the association of preoperative opioid
exposure with opioid consumption while adjusting for characteristics that differed between opioid-exposed and naïve participants. We used a Bernoulli distribution/logit link function to
examine outcomes for likelihood of opioid consumption and
refill, and used a negative binomial distribution/log link function for number of refills. A Gaussian distribution/identity link
function was used to examine opioid exposure and amount of
opioid prescribed in refills. Refills, number of refills, and amount
of opioids in refills were evaluated only in participants filling a
perioperative prescription.
In secondary analyses of the primary outcome, we examined
models of patient-reported postoperative opioid consumption
as a function of opioid exposure in the year before surgery
using four classifications of naïve, minimal, intermittent, and
chronic use and, in a sensitivity analysis, models based on total
opioid dose in the year before surgery. The significance level
was p<0.05. Analyses were performed using Stata/SE V.15.1
(StataCorp).

RESULTS

Among 58 468 potential participants at 70 hospitals, 26,001
participants (mean age 54, SD 16; 57% female) met inclusion
criteria for the primary analysis, including 6800 (26%) opioid-
exposed participants who filled at least one opioid prescription in the year before surgery and 19 201 (74%) opioid-naïve
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Patientcharacteristics by opioid exposure status in the year before surgery

Sample size, n

Opioid-naïve participants

Opioid-exposed participants

Overall

19,201

6800

26,001

53.9 (16.6)

53.6 (15.9)

53.8 (16.4)

P value

Demographics
Mean age (SD) in years

0.11

Age categories in years, n (%)
 18–29

1753 (9)

548 (8)

2301 (9)

 30–39

2397 (12)

931 (14)

3328 (13)

 40–49

3274 (17)

1275 (19)

4549 (17)

 50–59

3977 (21)

1346 (20)

5323 (20)

 60–64

2203 (11)

787 (12)

2990 (11)

 ≥65

5597 (29)

1913 (28)

7510 (29)

 Female

10,506 (55)

4270 (63)

14,776 (57)

 Male

8695 (45)

2530 (37)

11,225 (43)

 White, non-Hispanic

15,885 (83)

5682 (84)

21,567 (83)

 Black, non-Hispanic

1452 (8)

614 (9)

2066 (8)

 Hispanic

510 (3)

188 (3)

698 (3)

 Other/unknown

1354 (7)

316 (5)

1670 (6)

 Private

10,273 (54)

3016 (44)

13,289 (51)

 Medicare

5442 (28)

2084 (31)

7526 (29)

 Medicaid

2594 (14)

1401 (21)

3995 (15)

 Medicare and Medicaid

268 (1)

169 (2)

437 (2)

 Other

624 (3)

130 (2)

754 (3)

 1

1986 (10)

354 (5)

2340 (9)

 2

11 251 (59)

3552 (52)

14 803 (57)

 3

5660 (29)

2728 (40)

8388 (32)

 4 or 5

287 (1)

159 (2)

446 (2)

 Unknown

17 (<1)

7 (<1)

24 (<1)

 <25

3803 (20)

1222 (18)

5025 (19)

 25 to <30

6229 (32)

1933 (28)

8162 (31)

 30 to <35

4692 (24)

1692 (25)

6384 (25)

 ≥35

4427 (23)

1942 (29)

6369 (24)

 Unknown

50 (<1)

11 (<1)

61 (<1)

Tobacco use, n (%)

3504 (18)

1678 (25)

5182 (20)

Ascites, n (%)

44 (<1)

18 (<1)

62 (<1)

0.61

Bleeding disorder, n (%)

140 (1)

71 (1)

211 (1)

0.01

Congestive heart failure, n (%)

48 (<1)

22 (<1)

70 (<1)

0.31

Coronary artery disease, n (%)

726 (4)

360 (5)

1086 (4)

<0.001

Sex, n (%)

<0.001

<0.001

Race/ethnicity, n (%)

<0.001

Insurance type, n (%)

<0.001

Patient characteristics
ASA classification, n (%)

<0.001

Body mass index, n (%)

<0.001

<0.001

Chronic obstructive pulmonary disease, n (%)

649 (3)

466 (7)

1115 (4)

<0.001

Diabetes, n (%)

2111 (11)

906 (13)

3017 (12)

<0.001

Dialysis use, n (%)

41 (<1)

33 (<1)

74 (<1)

<0.001

Deep vein thrombosis/pulmonary embolus, n (%)

175 (1)

133 (2)

308 (1)

<0.001
<0.001

Hypertension, n (%)

7079 (37)

3005 (44)

10 084 (39)

Cancer, n (%)

1038 (5)

418 (6)

1456 (6)

Functional status, n (%)

19 064 (99)

6755 (99)

25 819 (99)

Sleep apnea, n (%)

3971 (21)

1764 (26)

5735 (22)

0.02
0.66
<0.001

Pneumonia, n (%)

7 (<1)

6 (<1)

13 (<1)

0.13

Immunosuppressed, n (%)

316 (2)

227 (3)

543 (2)

<0.001

Recent weight loss, n (%)

42 (<1)

22 (<1)

64 (<1)

0.13

Peripheral vascular disease, n (%)

74 (<1)

65 (1)

139 (1)

<0.001

Clinical characteristics
Continued

348
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Continued
Opioid-naïve participants

Opioid-exposed participants

Overall

 Abdominal hernia

859 (4)

445 (7)

1304 (5)

 Laparoscopic appendectomy

2282 (12)

498 (7)

2780 (11)

 Laparoscopic cholecystectomy

5649 (29)

2188 (32)

7837 (30)

 Laparoscopic colectomy

886 (5)

328 (5)

1214 (5)

 Laparoscopic hysterectomy

1742 (9)

765 (11)

2507 (10)

 Minor hernia

5830 (30)

1814 (27)

7644 (29)

 Open colectomy

480 (2)

184 (3)

664 (3)

 Total abdominal hysterectomy

570 (3)

231 (3)

801 (3)

 Vaginal hysterectomy

903 (5)

347 (5)

1250 (5)

 Elective

14 168 (74)

5393 (79)

19 561 (75)

 Emergent/Urgent

5033 (26)

1407 (21)

6440 (25)

 0

9803 (51)

3409 (50)

13 212 (51)

 1

4419 (23)

1554 (23)

5973 (23)

 2

2005 (10)

734 (11)

2739 (11)

 3

1147 (6)

453 (7)

1600 (6)

 4

707 (4)

261 (4)

968 (4)

 ≥5

1120 (6)

389 (6)

1509 (6)

Procedure type, n (%)

P value
<0.001

Surgical priority, n (%)

<0.001

Length of stay, n (%)

0.33

Opioid-naïve participants did not fill an opioid prescription in the year before surgery. Opioid exposed participants filled at least one opioid prescription in the year before
surgery.
χ2 statistical test used for all tests with exception of mean age (t-test).
ASA, American Society of Anesthesiologists.

participants with no opioid prescription fills in the year before
surgery (online supplemental efigure 1). Compared with opioid-
naïve participants, those with opioid exposure were more likely
to be female, have Medicaid insurance, have a higher ASA classification status, and have a higher BMI (table 1).
Patients with opioid exposure before surgery were more likely
to have comorbidities including bleeding disorders, coronary
artery disease, diabetes, dialysis use, hypertension, cancer, sleep
apnea, immunosuppression, and peripheral vascular disease.
They were also more likely to undergo elective surgery.
While most participants (89%) received preoperative opioid
doses of <50 OME per day on average, higher-risk exposures
of 50 to <100 OME (9%) and 100 OME or more (2%) did
occur. Among opioid-exposed participants, 52% (n=3524) met
criteria for minimal opioid exposure, while intermittent and
chronic exposure occurred in 38% (n=2599) and 10% (n=677),
respectively.
In unadjusted comparisons, opioid-exposed participants were
prescribed opioids at discharge more often (81% vs 66%) and
were prescribed larger total quantities (median OME 100; IQR
50, 200 vs 60; 0, 100) in the initial discharge prescription than
opioid-naïve participants.

adjusting for participant, clinical, and surgical factors, participants with any opioid exposure consumed 42.9 OMEs (95% CI
40.4 to 45.3) while opioid-naïve participants consumed 31.0
OMEs (95% CI 29.5 to 32.5), resulting in a difference of 11.9
OMEs (95% CI 9.8 to 14.0) (figure 2, online supplemental etable
2). In a secondary analysis adjusting for similar factors, participants with greater opioid exposures before surgery reported
consuming greater amounts of opioids at 30 days after surgery
in a dose-
dependent manner. Compared with opioid-
naïve
participants, consumption was higher among participants with
minimal preoperative exposure by 4.8 OME (95% CI 2.9 to 5.8)
and for intermittent exposure by 17.0 OME (95% CI 13.9 to
20.1). Chronic opioid exposure before surgery was associated
with the largest increase in consumption by 31.8 OMEs (95% CI
21.3 to 42.2) compared with opioid-naïve participants. A sensitivity analysis based on the dose of opioid in the year before
surgery revealed similar increases in consumption as the dose
of prescription opioids increased (online supplemental etable 3).
Finally, the likelihood of opioid consumption after surgery was
higher for opioid-exposed compared with opioid-naïve participants (adjusted rate 57% vs 54%; adjusted OR 1.16, 95% CI
1.09 to 1.24) (online supplemental etable 4).

Opioid consumption after discharge from surgery

Opioid Refills

Patients with any opioid exposure in the year before surgery
reported consuming greater amounts of opioids at 30 days after
surgery when compared with opioid-naïve participants across all
procedure types (figure 1). For unadjusted consumption, opioid
exposed participants consumed more than opioid-naïve participants (median OME 25; IQR 0, 75 vs 10; 0, 50, p<0.001).
Consumption was higher for opioid-exposed participants across
all procedures, with the greatest differences occurring for participants undergoing hysterectomy procedures, abdominal hernia
repair, and colectomy (online supplemental etable 1). After

Opioid prescription refills were identified in 19% (3481/18,281)
of participants who filled a perioperative prescription, and more
often among opioid-
exposed than opioid-
naïve participants
((39%, (2167/5,513) vs 10% (1314/12,768), p<0.001). In
adjusted models, the likelihood of receiving an opioid refill was
also higher for opioid-exposed participants (adjusted rate 35% vs
11%; adjusted OR 4.74, 95% CI 4.36 to 5.15) when compared
with opioid-naïve participants (figure 3). Opioid-exposed participants also received higher numbers of opioid prescription refills
in the first 30 days after surgery (adjusted incidence rate ratio
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Figure 1 Patient-reported opioid consumption at 30 days after
surgery by procedure type and opioid exposure status in the year
before surgery, unadjusted consumption amount in first 30 days after
surgery as reported by patients is unadjusted and expressed in pills
of oxycodone 5 mg (7.5 oral morphine equivalents (OME)). Boxplots
represent distribution of opioid consumption, with box representing 25–
75th percentile, and middle line of box 50th percentile/median. For all
procedures, opioid consumption at 10th and 25th percentiles was 0 pills
(0 OME). A p value for overall comparison of opioid-exposed and naïve
using the Mann-Whitney I test is <0.001. A p value for comparison of
procedures using Kruskal-Wallis is 0.001.

stewardship efforts should align prescriptions with the actual use
of opioids after surgery, which to date have focused primarily
on opioid-naïve patients, to better meet the needs of opioid-
exposed patients.
These data represent one of the first attempts at examining
self-reported opioid consumption by patients with opioid exposure in the year prior to surgery, and could provide practicing
clinicians with an additional resource to guide the management
of postoperative pain. For example, 75% of all opioid-exposed
patients used less than 17 pills. Further, 90% of opioid-exposed
patients reported consuming 20 pills or less after undergoing 8
of the 9 types of procedures included in this analysis, and opioid-
exposed patients accounted for two of every three refills given
after surgery. Although it has been shown previously that patients
with opioid exposure before surgery receive more frequent

3.97, 95% CI 3.71 to 4.25) (figure 4). Further, the average
amount of opioids filled through refills was higher for opioid-
exposed participants when compared with opioid-naïve participants (median OME 0, IQR 0, 200 vs 0; 0, 0, p<0.001). In
adjusted models, this difference persisted (adjusted refill OME
360; 95% CI 320 to 400 vs 27; 21, 33; adjusted difference refill
OME 333, 95% CI 292 to 374).

DISCUSSION

In this population-
based cohort study, exposure to prescription opioids in the year before undergoing general and gynecologic surgical procedures was associated with increases in the
consumption of opioids as reported by participants at 30 days
after surgery, as well as prescribing and refills. However, the
differences varied by procedure type and preoperative opioid
exposure. Compared with participants with no opioid exposure in the year before surgery, the amount of patient-reported
opioid consumption after surgery was similar among those with
minimal exposure (<90 pills and ≤1 month), greater for intermittent exposure, and greatest among participants with chronic
opioid exposure (≥9 months). These findings suggest opioid
350

Figure 3 Distribution of prescription opioid refills after surgery by
opioid exposure status in the year before surgery rates of consumption
and refill reflect adjustment in logistic regression models for age, sex,
race/ethnicity, insurance, American Society of Anesthesiologists physical
classification, 13 other patient comorbidities, surgery type, and surgery
priority. Naïve indicates no opioid fills in year before surgery. Bars
represent 95% CIs.
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Figure 2 Adjusted patient-reported opioid consumption at 30 days
after surgery by opioid exposure status in the year before surgery
consumption amount is mean total reported opioid use and reflects
adjustment in linear regression models for age, sex, race/ethnicity,
insurance, American Society of Anesthesiologists physical classification,
13 other patient comorbidities, surgery type, and surgery priority. naïve
indicates no opioid fills in year before surgery. bars represent 95%
CIs. A p value for trend of opioid consumption by preoperative opioid
exposure status is <0.001 for both unadjusted (linear-by-linear test)
and adjusted groups (orthogonal polynomial contrast test). To calculate
number of pills of oxycodone 5 mg, divide oral morphine equivalents
(OME) by 7.5. For example, 30 OME is 4 pills of oxycodone 5 mg while
60 OME is eight pills.

Original research

and larger postoperative opioid prescriptions, this prior work
did not capture self-reported consumption of pain medication
after surgery.3 9 14 Consumption of pain medication prescribed
to surgical patients after discharge from surgery has previously
been shown to differ markedly from self-
reported consumption for opioid-naïve patients.15 Quality improvement efforts to
address the oversupply of prescription opioids among opioid-
naïve surgical patients have led to reductions in prescribing by
50% or more without compromising patient-reported outcomes
such as pain or satisfaction.6 7 16 Achieving similar outcomes for
surgical patients with prior opioid exposure is likely to require
approaches that account for the additional complexities of
caring for surgical patients with chronic pain who have recently
or currently taken prescription opioids.17
The dose–response relationship of opioid consumption with
opioid exposure may seem intuitive but has important implications for the care of surgical patients. First, opioid use and
prescribing was elevated even among opioid-exposed patients
without chronic use before surgery, for whom the expectation
of continued use would not be high. Second, this work suggests
that opioid exposure of any type has an association with higher
consumption, and it is important to quantify the amount of opioid
exposure in the year before surgery. For example, small opioid
exposures before surgery may result in increases in consumption equivalent to one opioid pill or less, which may not equate
to a clinically meaningful difference when recently developed
guidelines from Michigan OPEN, the Mayo Clinic, and Johns
Hopkins recommend prescribing up to ten opioid pills after
many types of surgery for opioid-naïve patients.18–20 However,

CONCLUSION

In a large cohort of patients undergoing general and gynecologic surgery, exposure to prescription opioids in the year before
surgery was associated with higher opioid consumption after
surgery. Further, higher consumption was identified among
patients with higher preoperative opioid exposures in a dose-
dependent manner. Opioid exposure in the year before surgery
represents a critical characteristic that should be considered
when crafting opioid stewardship efforts to optimize opioid
prescribing for the treatment of acute pain in the context of
surgery.
Author affiliations
1
Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan, USA
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Figure 4 Percentage of participants who refilled opioid prescriptions
after surgery according to opioid exposure status in the year before
surgery number of refills determined by opioid prescriptions in state
prescription drug monitoring database. Results are unadjusted. For
opioid naïve group, percentages without rounding add to 100%.

the same may not be true for larger opioid exposures over the
course of the year prior to surgery. Additional evidence to guide
opioid prescriptions at the time of discharge from surgery needs
to clarify how discharge prescriptions should be modified based
on opioid exposure before surgery, if at all. Surgical teams also
need efficient ways to determine opioid exposure in the year
before surgery through tools that efficiently integrate data from
patients with queries of the PDMP, which track prescriptions for
controlled substances in 49 of 50 states but lack consistent use in
some surgical settings.21 22
Finally, this work reinforces the finding that patients with
opioid exposure before surgery have greater and more complex
comorbidities, as seen by higher ASA physical status classification scores, greater BMI, and higher diagnoses for diseases such
as chronic obstructive pulmonary disease, among others. The
greater burden of comorbidities aligns with prior studies showing
these patients have higher baseline health risks, which reinforces
the need for screening programs to identify these risks to allow
for potential mitigation strategies.23 Among patients prescribed
opioids, comorbidities such as obesity and chronic obstructive
pulmonary disease increase the risk for respiratory depression
and compromise, and lead to differences in the dose response
curves with respect to analgesia and respiratory depression.24 It
is possible that patients with higher opioid exposure may require
higher doses to achieve pain relief, but with markedly increased
risk of respiratory depression. As such, prescribing for these
vulnerable individuals requires careful consideration, including
care coordination and risk mitigating strategies, such as coprescribing with naloxone.
This study should be placed in the context of several limitations. First, these associations should not be classified as causal,
though this represents one of the largest studies with patients
reporting actual consumption after surgery, and multiple
measures of preoperative opioid exposure suggest greater postoperative opioid utilization. Second, unmeasured confounding
may be present, though adjusted models account for several
relevant patient, clinical, and operative variables. Third, data on
consumption of opioids relies on patient report, which has the
potential to differ from actual use. In response, we employed
the novel capture of data on controlled substance use by linking
surgical and PDMP data. This permitted identification of
discrepancies in opioid prescription fills as reported by patients
and those as cataloged in the PDMP, with such patients excluded
from the study. Fourth, the analysis occurs in the context of a
dynamic surgical quality collaborative with robust efforts to
modify opioid prescribing at discharge from surgery, with such
efforts resulting in significant reductions of prescription opioids
that may attenuate differences in utilization for opioid-naïve and
opioid-exposed surgical patients.7 8
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